COV Cleo Diagnostics Ltd
Healthcare · Medical Devices
· website
$0.34
52wk 0.27 – 0.90
Overall
35.1
Value
45.5
Growth
0.0
Health
100.0
Quality
0.0
Momentum
16.9
Dividend
—
Price
About Cleo Diagnostics Ltd
Cleo Diagnostics Ltd, a biotechnology company, engages in the development and patent of a blood test for the detection of ovarian cancer in Australia. The company offers CleoDX pre-surgical triage tests which measures a combination of five biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing intellectual property, testing the IP, and securing patents. Cleo Diagnostics Ltd was incorporated in 2021 and is based in Melbourne, Australia.
Price analytics
Returns
| 1 day | 7.8% |
| 1 week | 16.9% |
| 1 month | -13.8% |
| 3 months | -30.3% |
| 6 months | -36.7% |
| 1 year | -2.8% |
| 3 years | 91.7% |
Risk
| Volatility (1y ann.) | 84.1% |
| Beta vs ASX 200 | 1.25 |
| Sharpe (1y) | 0.33 |
| VaR 95% (1-day) | -7.2% |
| Max drawdown (1y) | -67.6% |
| Off 1-year high | -60.1% |
Technicals
| RSI(14) | 52 |
| vs 50DMA | 3.7% |
| vs 200DMA | -32.7% |
| Trend | Death cross |
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value
45.5
Trailing P/E
—
Forward P/E
—
PEG ratio
—
EV / EBITDA
100
Price / Book
0
Price / Sales
0
Growth
0.0
Revenue growth (1y)
0
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health
100.0
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
—
Current ratio
100
Debt / Equity
—
Quality (Profitability & Cash Flow)
0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income
—
No meaningful dividend — pillar excluded from the overall score.
Momentum
16.9
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
68
Position in 52-week range
12
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
Score history
Key metrics
Market cap
$49.12M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
-0.04
Dividend yield
—
Payout ratio
0.0%
Beta
0.36
EV / EBITDA
-7.32
Price / Book
9.32
ROE
-109.5%
Operating margin
-330.8%
Net margin
0.0%
Total cash
$6.22M
Total debt
$0
Current ratio
3.80
Debt / Equity
—
Free cash flow
$-2.56M
Avg volume
162,301
Latest annual results
(FY ending 30 Jun 2026)
- Revenue—
- Gross profit—
- Operating income-$7.89M
- Net income-$5.94M
- Diluted EPS-0.04
- Free cash flow-$4.95M
- Net debt-$6.22M